Hay, Charles R.M.

Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom

Hay, C. R. M., Palmer, B., Chalmers, E., Liesner, R., Maclean, R., Rangarajan, S., Williams, M., Collins, P. W., & on behalf of United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) (2011) · Blood

Hemophilia Treatment and ResearchPlatelet Disorders and Treatments

Cited by 174

Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII

RECHT, M., NEMES, L., MATYSIAK, M., MANCO‐JOHNSON, M., LUSHER, J., SMITH, M., MANNUCCI, P., HAY, C., ABSHIRE, T., O’BRIEN, A., et al. (2009) · Haemophilia

Hemophilia Treatment and ResearchPlatelet Disorders and Treatments

Cited by 92